Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.

Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H

JAMA psychiatry1 Jan 2025Cited by 102 (Europe PMC)

PMID39535805PMCIDPMC11561716DOI10.1001/jamapsychiatry.2024.3599PepBankPUB-39535805

Summary

ImportancePreliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption.ObjectiveTo test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.Design, setting, and participantsThis cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023. The population-based cohort was identified from registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.ExposuresThe primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.Main outcomes and measuresThe primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model. Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.ResultsThe cohort included 227 866 individuals with AUD; 144 714 (63.5%) were male and 83 154 (36.5%) were female, with a mean (SD) age of 40.0 (15.7) years. Median (IQR) follow-up time was 8.8 (4.0-13.3) years. A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization. Use of any AUD medication was associated with a modestly decreased risk (aHR, 0.98; 95% CI, 0.96-1.00). Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).Conclusions and relevanceAmong patients with AUD and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In Swedish residents with alcohol use disorder, semaglutide use was associated with lower AUD-hospitalization risk than nonuse periods for the same individual (aHR 0.64; 95% CI 0.50-0.83).
In plain wordsIn Swedish people with alcohol use disorder, semaglutide use was linked to fewer alcohol-related hospitalizations than their nonuse periods.
Peptide
Semaglutide
Outcome
DecreaseAlcohol use disorder hospitalization
Study
n = 4,321
Comparator
Nonuse
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.64
native use versus same-individual nonuse periods; 95% CI 0.50-0.83
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580501
02HumanObservational studyEfficacy outcome
In Swedish residents with alcohol use disorder, liraglutide use was associated with lower AUD-hospitalization risk than nonuse periods for the same individual (aHR 0.72; 95% CI 0.57-0.92).
In plain wordsIn Swedish people with alcohol use disorder, liraglutide use was linked to fewer alcohol-related hospitalizations than their nonuse periods.
Peptide
Liraglutide
Outcome
DecreaseAlcohol use disorder hospitalization
Study
n = 2,509
Comparator
Nonuse
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.72
native use versus same-individual nonuse periods; 95% CI 0.57-0.92
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580502
03HumanObservational studyEfficacy outcome
In Swedish residents with alcohol use disorder, semaglutide use was associated with lower SUD-hospitalization risk than nonuse periods for the same individual (aHR 0.68; 95% CI 0.54-0.85).
In plain wordsIn Swedish people with alcohol use disorder, semaglutide use was linked to fewer substance-related hospitalizations than their nonuse periods.
Peptide
Semaglutide
Outcome
DecreaseSubstance use disorder hospitalization
Study
n = 4,321
Comparator
Nonuse
Analysis
Secondary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.68
native use versus same-individual nonuse periods; 95% CI 0.54-0.85
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580503
04HumanObservational studyEfficacy outcome
In Swedish residents with alcohol use disorder, semaglutide use was associated with lower somatic-hospitalization risk than nonuse periods for the same individual (aHR 0.78; 95% CI 0.68-0.90).
In plain wordsIn Swedish people with alcohol use disorder, semaglutide use was linked to fewer general medical hospitalizations than their nonuse periods.
Peptide
Semaglutide
Outcome
DecreaseSomatic hospitalization
Study
n = 4,321
Comparator
Nonuse
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.78
native use versus same-individual nonuse periods; 95% CI 0.68-0.90
Source sentences
Summary
Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580505
05HumanObservational studySafety outcome
In Swedish residents with alcohol use disorder, semaglutide use was not associated with suicide attempts versus nonuse periods for the same individual (aHR 0.55; 95% CI 0.23-1.30).
In plain wordsIn Swedish people with alcohol use disorder, semaglutide use was not linked to suicide attempts versus their nonuse periods.
Peptide
Semaglutide
Outcome
No significant changeSuicide attempt
Study
n = 4,321
Comparator
Nonuse
Analysis
Secondary
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.55
native use versus same-individual nonuse periods; 95% CI 0.23-1.30
Source sentences
Summary
Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580507
06HumanObservational studyEfficacy outcome
In Swedish residents with alcohol use disorder, liraglutide use was associated with lower SUD-hospitalization risk than nonuse periods for the same individual (aHR 0.78; 95% CI 0.64-0.97).
In plain wordsIn Swedish people with alcohol use disorder, liraglutide use was linked to fewer substance-related hospitalizations than their nonuse periods.
Peptide
Liraglutide
Outcome
DecreaseSubstance use disorder hospitalization
Study
n = 2,509
Comparator
Nonuse
Analysis
Secondary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.78
native use versus same-individual nonuse periods; 95% CI 0.64-0.97
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580504
07HumanObservational studyEfficacy outcome
In Swedish residents with alcohol use disorder, liraglutide use was associated with lower somatic-hospitalization risk than nonuse periods for the same individual (aHR 0.79; 95% CI 0.69-0.91).
In plain wordsIn Swedish people with alcohol use disorder, liraglutide use was linked to fewer general medical hospitalizations than their nonuse periods.
Peptide
Liraglutide
Outcome
DecreaseSomatic hospitalization
Study
n = 2,509
Comparator
Nonuse
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
0.79
native use versus same-individual nonuse periods; 95% CI 0.69-0.91
Source sentences
Summary
Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580506
08HumanObservational studySafety outcome
In Swedish residents with alcohol use disorder, liraglutide use was not associated with suicide attempts versus nonuse periods for the same individual (aHR 1.08; 95% CI 0.55-2.15).
In plain wordsIn Swedish people with alcohol use disorder, liraglutide use was not linked to suicide attempts versus their nonuse periods.
Peptide
Liraglutide
Outcome
No significant changeSuicide attempt
Study
n = 2,509
Comparator
Nonuse
Analysis
Secondary
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio
1.08
native use versus same-individual nonuse periods; 95% CI 0.55-2.15
Source sentences
Summary
Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580508
09HumanObservational studyOther
In Swedish residents aged 16-64 with AUD, semaglutide had the lowest reported AUD-hospitalization risk association; the specific ranking reference was unstated.
In plain wordsIn Swedish residents with AUD, semaglutide had the lowest reported alcohol-related hospitalization risk association; the ranking comparison was unspecified.
Peptide
Semaglutide
Outcome
Not applicableAUD hospitalization risk-association ranking
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580509
10HumanObservational studyOther
In Swedish residents aged 16-64 with AUD, semaglutide had the lowest reported SUD-hospitalization risk association; the specific ranking reference was unstated.
In plain wordsIn Swedish residents with AUD, semaglutide had the lowest reported substance-related hospitalization risk association; the ranking comparison was unspecified.
Peptide
Semaglutide
Outcome
Not applicableSUD hospitalization risk-association ranking
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580510
11HumanObservational studyOther
In Swedish residents aged 16-64 with AUD, liraglutide had the second lowest reported AUD-hospitalization risk association; the specific ranking reference was unstated.
In plain wordsIn Swedish residents with AUD, liraglutide had the second lowest reported alcohol-related hospitalization risk association; the ranking comparison was unspecified.
Peptide
Liraglutide
Outcome
Not applicableAUD hospitalization risk-association ranking
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580511
12HumanObservational studyOther
In Swedish residents aged 16-64 with AUD, liraglutide had the second lowest reported SUD-hospitalization risk association; the specific ranking reference was unstated.
In plain wordsIn Swedish residents with AUD, liraglutide had the second lowest reported substance-related hospitalization risk association; the ranking comparison was unspecified.
Peptide
Liraglutide
Outcome
Not applicableSUD hospitalization risk-association ranking
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization.
6 context sentences(design, population, supporting numbers)
Summary · context
To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.
Summary · context
This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023.
Summary · context
Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.
Summary · context
The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.
Summary · context
The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model.
Summary · context
Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt.
Show in the study text Report a problemFND-3953580512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06745128

Tirzepatide for Obesity and Meth Use Disorder

University of Texas Southwestern Medical Centern = 353 Feb 2025 to 12 Feb 2026

Obesity · Methamphetamine Use Disorder

Trial page ClinicalTrials.govUpdated 28 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC